AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
AK112(一种新型PD-1/VEGF双特异性抗体)联合化疗治疗晚期非小细胞肺癌(NSCLC)患者:一项开放标签、多中心、II期临床试验
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.102106
Zhao, Yuanyuan; Chen, Gang; Chen, Jianhua; Zhuang, Li; Du, Yingying; Yu, Qitao; Zhuang, Wu; Zhao, Yanqiu; Zhou, Ming; Zhang, Weidong; Zhang, Yu; Wan, Yixin; Li, Wenting; Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Yang, Yunpeng; Fang, Wenfeng; Huang, Yan; Zhang, Li
肺癌
肿瘤
肿瘤免疫
EGF
CLC
细胞生物学
VEGF
PD-1